SCIT for Allergies: Protocols, Extract Dosing, and Evidence by Allergen

SCIT stands for subcutaneous immunotherapy — the clinical term for allergy shots. 'Subcutaneous' refers to the injection route: allergen extract is delivered under the skin (subcutaneously) rather than into a muscle or vein. 'Immunotherapy' refers to the treatment category that modifies the immune response to the allergen rather than simply blocking symptoms. SCIT is distinguished from SLIT (sublingual immunotherapy), which delivers allergen under the tongue, and OIT (oral immunotherapy), which is used for food allergies. In clinical notes and literature, SCIT is the preferred term among allergists and immunologists. Patients may also encounter it as AIT (allergen immunotherapy), the broadest category term used in guidelines from AAAAI, ACAAI, and EAACI.

SCIT is delivered via three buildup protocols that differ in how rapidly the maintenance dose is reached. Conventional SCIT administers one injection per visit, one to two times weekly, reaching maintenance in 3-7 months after approximately 25-30 injections — the lowest risk profile. Cluster SCIT administers two to three injections per visit with 30-minute intervals between doses, reaching maintenance in 4-8 weeks with approximately 50% fewer total visits than conventional (Calabria, Ann Allergy 2023); premedication with antihistamines is routinely recommended. Rush SCIT compresses buildup to 1-3 days with injections every 15-60 minutes under continuous medical supervision; premedication with H1 antihistamines, H2 blockers, corticosteroids, and sometimes omalizumab is required; systemic reaction rates of 20-38% occur even with premedication (Portnoy et al., Ann Allergy 1994), making this a specialized-setting protocol.

The AAAAI/ACAAI Practice Parameter (Cox et al., JACI 2011, Box 8) defines the maintenance dose target as 5 to 20 micrograms of major allergen per 0.5 mL injection for inhalant allergens. For standardized products, this corresponds to 1,000-4,000 BAU for grass pollens and cat, and 500-2,000 AU for house dust mites. Allergen-specific targets are: grass (Phl p 5) 7-19 mcg, ragweed (Amb a 1) 6-24 mcg, cat (Fel d 1) 11-17 mcg with 15 mcg shown most consistently effective, and dust mite (Der p 1) 7-12 mcg. For Hymenoptera venom, the maintenance target is 100 micrograms per venom. Non-standardized extracts (most trees, weeds, molds, dog) are typically dosed at 3,000-5,000 PNU or 0.5 mL of 1:100 weight-to-volume concentrate, with major allergen content variable between manufacturers.

The most clinically significant contraindication to SCIT is severe or uncontrolled asthma — multiple guidelines including GINA 2023, EAACI 2018, and the AAO-HNS 2024 CPG use an FEV1 below 70% predicted as a relative-to-absolute contraindication. Uncontrolled asthma was the dominant risk factor in 4 of 7 SCIT fatalities in the AAAAI/ACAAI 2008-2016 surveillance. Beta-blocker use is a relative contraindication because beta-blockers impair the epinephrine response to anaphylaxis, though contemporary data (Sturm et al., Allergy 2021, n=1,425) suggest the risk has been overstated for venom immunotherapy. Pregnancy is a contraindication to initiating SCIT but not to continuing maintenance in patients already receiving it. Active malignancy, severe immunodeficiency, and active autoimmune disease are traditionally listed as contraindications, though evidence is largely theoretical (Pitsios, EAACI 2015).

For allergens covered by FDA-approved SLIT tablets — grass pollen, ragweed, five-grass mix, and house dust mite — efficacy data are broadly comparable between SCIT and SLIT. Nelson's 2015 Bayesian network meta-analysis found no significant difference between SCIT and SLIT-tablet for grass pollen (symptom SMD difference 0.0145, 95% CrI -0.19 to 0.23). For allergens without FDA-approved tablets — cat dander, most mold species, dog dander, other tree pollens, and mixed multi-allergen protocols — SCIT remains the only well-evidenced option. Cat dander SCIT at 15 mcg Fel d 1 maintenance produced approximately 72% symptom reduction in a double-blind exposure study (Varney et al., Clin Exp Allergy 1997), while no FDA-approved cat SLIT tablet exists. Cockroach SCIT failed its primary clinical endpoint in the 2024 CRITICAL trial, and practice parameters do not endorse SCIT for molds beyond Alternaria.

Rush immunotherapy compresses the SCIT buildup phase into 1-3 days, with allergen injections administered every 15-60 minutes under continuous medical supervision in a closely monitored clinical setting. Because the accelerated schedule carries substantially higher systemic reaction risk than conventional SCIT — 20-38% even with aggressive premedication (Portnoy et al., Ann Allergy 1994) — it is reserved for patients with strong clinical rationale for rapid achievement of the maintenance dose: those with severe seasonal disability who cannot wait through months of conventional buildup, or occasionally patients with venom hypersensitivity who need rapid protection. Premedication requirements include H1 antihistamines, H2 blockers, a leukotriene antagonist, oral corticosteroids, and sometimes omalizumab pretreatment 8-12 weeks prior (Casale et al., JACI 2006 showed a 5-fold SR reduction with omalizumab). Rush SCIT is not appropriate for moderate-to-severe uncontrolled asthma.

Missed SCIT doses require dose adjustment based on the duration of the gap, though adjustment schedules are consensus-based rather than RCT-derived. During buildup, gaps of 2-3 weeks typically mean repeating the last dose; gaps of 3-4 weeks require stepping back by one or two doses; gaps of 90 days or more generally require restarting from the first vial. During maintenance, the dose can typically be maintained for gaps up to about 5 weeks; gaps of 5-7 weeks require a 25% reduction; gaps of 7-11 weeks require roughly a 45% reduction; and gaps of 3-4 months or more require restarting from the beginning. Larenas-Linnemann et al. (Ann Allergy Asthma Immunol 2020) compiled these institutional protocols explicitly noting the absence of prospective evidence to support any specific schedule. From a safety standpoint, a 2025 AAAAI surveillance analysis found that advancing dose after even 7-21 day maintenance gaps significantly increased grade 3-4 reaction rates.